Oncogenic mutations in KRAS or NRAS have been found, though in reduced numbers of CLL patients (32 out of 1308, https://www.cbioportal.org/), and no mutations have been so far identified by GWAS in HRAS or RRAS2. Therefore, 97.5% of human CLL appear without oncogenic mutations in known RAS drivers. Here, KRAS is linked to B-cell chronic lymphocytic leukemia.